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Abstract. Transgenic mice were generated with a fu- 
sion gene carrying a portion of the murine myelin pro- 
teolipid protein (PLP) gene, including the first intron, 
fused to the E. coli LacZ gene. Three transgenic lines 
were derived and all lines expressed the transgene in 
central nervous ystem white matter as measured by a 
histochemical ssay for the detection of/~-galactosi- 
dase activity. PLP-LacZ transgene xpression was 
regulated in both a spatial and temporal manner, con- 
sistent with endogenous PLP expression. Moreover, 
the transgene was expressed specifically in oligoden- 
drocytes from primary mixed glial cultures prepared 
from transgenic mouse brains and appeared to be de- 
velopmentally regulated in vitro as well. Transgene 
expression occurred in embryos, presumably in pre- or 
noumyelinating cells, rather extensively throughout the 
peripheral nervous ystem and within very discrete 
regions of the central nervous ystem. Surprisingly, 
/~-galactosidase activity was localized predominantly in
the myelin in these transgenic animals, suggesting that 
the NH2-terminal 13 amino acids of PLP, which were 
present in the PLP-LacZ gene product, were sufficient 
to target he protein to the myelin membrane. Thus, 
the first half of the PLP gene contains equences suf- 
ficient to direct both spatial and temporal gene regula- 
tion and to encode amino acids important in targeting 
the protein to the myelin membrane. 
M 
YELIN is a highly specialized extension of the 
plasma membrane elaborated by oligodendrocytes 
in the central nervous system (CNS) 1 and by 
Schwann cells in the peripheral nervous ystem (PNS). My- 
elin ensheathes a segment of an axon, forming a tightly com- 
pacted multilamellar structure (Raine, 1984), which func- 
tions to promote saltatory conduction of the nerve impulse 
(Huxley and Staemptti, 1949). Myelination is essential for 
nervous ystem function, with dysmyelination resulting in 
devastating forms of mental retardation. In addition, demye- 
lination in the adult, such as in multiple sclerosis in humans, 
results in serious motor and sensory disorders. Myelination 
involves the coordinate xpression of a small set of myelin- 
specific genes (for review see Campagnoni, 1988; Campa- 
gnoni and Macklin, 1988; Ikenaka et al., 1991; Mikoshiba 
et al., 1991). One of these genes, the proteolipid protein 
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(PLP) gene provides an excellent model to study gene regu- 
lation for many reasons. (a) The PLP gene is abundantly ex- 
pressed. Its gene products constitute roughly 50 % of the to- 
tal protein found in adult CNS myelin (Eng et al., 1968; 
Norton and Poduslo, 1973). (b) Its expression is cell-type 
specific, primarily restricted to oligodendrocytes. (c) The 
gene is regulated evelopmentally with peak expression oc- 
curring during the early postnatal period in rodents. (d) PLP 
gene expression can be studied in vitro in primary cultured 
oligodendrocytes in the absence of any neural signals 
(Dubois-Dalcq et al., 1986). (e) Mutations in this gene are 
devastating, and animals such as the jimpy mouse or the 
myelin-deficient rat are severely compromised, ying within 
the first two months after birth. (f) The PLP gene products 
are targeted specifically to the myelin membrane. 
The PLP gene is present as a single copy in the genome 
(Milner et al., 1985; Diehl et al., 1986; Gardinier et al., 
1986) located on the X chromosome (Willard and Riordan, 
1985; Mattei et al., 1986). The general gene structure in the 
mouse (Macklin et al., 1987, 1991; Ikenaka, 1988) and hu- 
man (Diehl et al., 1986) is quite similar; roughly 17 kb of 
DNA encompass even exons with a large first intron (7-8 
kb). The coding sequence of the PLP gene is highly con- 
served with 100% identity among the mouse, rat, and human 
sequences atthe amino acid level and >95 % identity at the 
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nucleotide l vel. As well, there exists a high degree of con- 
servation for the 5'-and 3'-untranslated regions of the gene, 
even extending into the 5'-flanking DNA (Macklin et al., 
1987). 
Two protein products are generated from the PLP gene, 
by use of an alternative splice site within exon 3; PLP which 
contains 276 amino acids and a related protein, DM-20, 
which does not contain PLP residues 116-150 (Macklin et 
al., 1987; Nave et al., 1987; Simons et al., 1987). DM-20 
protein is expressed prior to PLP during development but as 
development proceeds, PLP becomes the predominant pro- 
tein (Kronquist et al., 1987; Gardinier and Macklin, 1988; 
LeVine et al., 1990; Schindler et al., 1990). Likewise, the 
transcripts encoding both proteins are temporally regulated 
(LeVine et al., 1990) with the expression of DM-20 mRNA 
preceding that of PLP mRNA and occurring embryonically 
in the mouse (Pham-Dinla et al., 1991; Ikenaka et al., 1992; 
Timsit et al., 1992a). Although PLP expression has been 
demonstrated in Schwann cells, it may not be incorporated 
into myelin sheaths (Puckett et al., 1987; Kamholz et al., 
1992). Unlike the developmental switch observed in oligo- 
dendrocytes, both DM-20 mRNA and protein expression are 
higher than PLP mRNA and protein in rat sciatic nerve at 
postnatal day 14 (Pham-Dinh et al., 1991). 
The transcriptional regulatory elements controlling PLP 
gene expression have been difficult o map in vitro, primarily 
due to a paucity of PLP-expressing cell lines. Several recent 
studies have used deletion-transfection analysis to localize 
transcriptional regulatory elements within the PLP gene. 
While these studies identified elements that modulate PLP 
gene expression i both a positive and negative fashion, none 
of these lements were sufficient to direct issue-specific ex- 
pression of the PLP gene entirely. In these experiments, 
0.3-5.0 kb of Y-flanking DNA of the PLP gene was used to 
drive reporter gene expression. The results indicate that the 
PLP promoter can be transcribed in a number of cell types, 
including many cells that do not express the PLP gene nor- 
maUy. Mouse PLP-luciferase chimeric genes had significant 
transcriptional activity in either hamster glial cells or mouse 
hepatoma cells (Cook et al., 1992). Likewise, fusion genes 
containing rat Y-flanking PLP DNA promoted chloram- 
phenicol acetyl transferase (CAT) expression in both glial 
and nonglial cells (Nave and Lemke, 1991). In contrast, hu- 
man PLP sequences directed high level CAT expression i  
human astroglial cells but not in nonglial cells (Berndt et al., 
1992), suggesting that this construct might contain some 
tissue-specific elements, although it is unclear why astroglial 
cells should express the reporter gene, since they do not ex- 
press PLP. Taken together, these studies uggest that the 5'- 
flanking DNA of the PLP promoter can direct gene expres- 
sion in many cells, while sequences important to restricting 
tissue-specific expression of the PLP gene may reside else- 
where in the gene. Since the structure of the PLP gene is 
highly conserved and the first intron accounts for almost half 
of the gene, we hypothesized that a tissue specific element(s) 
might reside within intron 1. To test his, transgenic animals 
were generated using a PLP-LacZ fusion gene which con- 
tained intron 1 and coded for the first 13 amino acids of PLP. 
Three transgenlc ines were derived and all lines expressed 
the transgene (/~-galactosidase) both spatially and tem- 
porally consistent with endogenous PLP expression. Trans- 
gene expression was maintained in primary cultured oligo- 
dendrocytes thus effectively tagging these cells for future use 
in transplantation studies. Surprisingly, a greater level of 
transgene expression was observed in the embryonic PNS as 
opposed to the CNS. In adult animals, B-galactosidase activ- 
ity was present in the myelin, suggesting that the first 13 
amino acids were sufficient to target he protein appropri- 
ately. Thus, these transgenic animals provide an extremely 
potent model to study gene regulation i  the developing ner- 
vous system. 
Materials and Methods 
Transgenic Plasmid Construction 
A KpnI-ApaI fragment encompassing the latter two thirds of PLP intron 
1 and the first part of exon 2 was isolated from genomic lambda clone 9a 
(Macklin et al., 1987). The ApaI site was converted to a SpH site by 
removal of the Y-overhang with T4 DNA polymerase and the subse- 
quent ligation of a SphI synthetic linker (5"GC~ATGCC-3'; Promega, 
Madison, WI). The KpnI-SphI fragment was subcloned into the corre- 
sponding sites in pGEM-7Zf(-) (Promega) and the resulting plasmid 
was designated KS-5.5. A ClaI-KpnI fragment from lambda KK1 (Macklin 
et al., 1991) containing PLP 5"flanking DNA, all of exon 1 and the first 
third of intron 1 was inserted upstream of PLP sequences inKS-5.5 at the 
ClaI and KpnI sites, thus regenerating PLP intron 1. This plasmid was 
termed CS(+). A LacZ expression cassette containing the HindIII-BamHI 
fragment from plasmid pCHll0 (Pharma¢ia Biotech Inc., Piscataway, NJ) 
was subcloned into pBluescript KS(+) (Stratngene, LaJolla, CA) and desig- 
nated pGAL5 (gift of N. Mori and D. Anderson, California Institute of 
Technology, Pasadena, CA). The HindllI site was converted to a SphI site 
by a fill-in reaction with DNA polymerase I large fragment and four dNTPs 
followed by the addition ofa Sphl inker, generating plasmid pGALSph. The 
ApaI-SphI PLP fragment from CS(+) was llgated into the ApaI and Sphl 
sites of pGALSph generating plasmid AS(+)GAL. To remove an in-frame 
stop codon downstream from the PLP initiating methionine, pGAL5 was 
digested with KpnI to delete a239-bp fragment and the remaining KpnI site 
was converted to a SphI site as described above, yielding plasmid pGALAK. 
The final construct was designated PLP(+)Z and it was generated by replac- 
ing the LacZ expression cassette (SphI-NotI fragment) in AS(+)GAL with 
the analogous Sphl-NotI fragment from pGALAK which essentially re- 
moved the in-frame stop codon. Thus PLP(+)Z contains 2.4 kb of 5'- 
flanking PLP DNA, all of exon 1 and intron 1, and the first 37 bp of PLP 
exon 2 ligated to a trpS-LacZ fusion gene and SV-40 polyadenylation sig- 
nals (nucleotides 209-3736 of pCH110). 
Production of Transgenic Mice 
PLP(+)Z was digested with ApaI and NotI and fractionated on a 0.7% 
agarose gel. A 14-kb band of DNA was excised from the gel and electro- 
eluted. The DNA was subjected to several extractions with phenol/chloro- 
form and then precipitated twice with 3 M sodium acetate and ethanol. The 
precipitate was redissolved inTE (10 mM Tris, 1 mM EDTA) at a concen- 
tration of '~ 200 copies/pl. Transgenic animals were generated by the injec- 
tion of DNA into pronuclei of BDF2-fertilized mouse ggs (Hogan et al., 
1986; Readhead et al., 1987). Fertilized eggs were incubated overnight in 
M16 media (Hogan et al., 1986) in a 5% CO2 incubator at 37°C, and the 
next day, 15 to 20 two-cell stage embryos were transferred into the left 
oviduct of BDF1 pseudopregnant mouse. The mice were allowed to develop 
to term. At 3 wk of age, the animals were weaned and screened for transgene 
integration. 
Screening for Potential Transgenic Founders 
A piece of tail was biopsied from potential founder mice under anesthesia. 
DNA was isolated from tail biopsies by incubation overnight with pro- 
teinase K (100 #g/ml) in 50 mM Tris, 100 mM EDTA, at 50°C followed 
by one extraction with phenol, two extractions with phenol/chloroform (1:1) 
and a final extraction with chloroform alone. The DNA was precipitated 
with 3 M sodium acetate and ethanol. The DNA was resuspended with TE. 
The transgene was identified by Southern blot analysis. Genomic DNA (10 
~g) was digested with BamHI, electrophoresed on 0.7 % agarose gels, and 
transferred to nitrocellulose. The blots were hybridized to random primed 
LacZ sequences (SphI-NotI fragment from pOALAK). 
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[3-Galactosidase Histochemistry 
B-galactosidase-expressing cellswere identified in mice by staining with 
X-gal (5-bromo-4-chloro-3-indolyl-B-galactopyranoside; Pr mega) as de- 
scribed by Sanes et al. (1986) or with Bluo-gal (halogenated indolyl-/3- 
v-galactoside; GIBCO BRL Life Technologies, Inc., Gaithersburg, MD) as 
described by l.x~wy et al. 0991). Briefly, mice were anesthetized with 
halothane and perfused intracardially with PBS followed by 0.5% 
paraformaldehydeq.0% glntaraldehyde in PBS, pH 7.3, and finally in the 
same fixative containing 10% sucrose. Perfnsed animals were left un- 
disturbed for 1 h after which tissues were dissected out and immersed in 
the fixative containing 10% sucrose. Upon dropping, tissue sank in the same 
fixative containing 25% sucrose (usually overnight at 40C), and was stored 
at -80"C until cryostat sectioning (20-30 ttm). The X-gal stain consisted 
of 1 mg/ml X-gal, 5 mM potassium ferrieyanide, 5 mM potassium fer- 
roeyanide, 2 mM MgC12, 0.02% NP-40, and 0.01% sodium deoxycholate in 
PBS. The Bluo-gal stain consisted of 2 mM Bluo-gal, 16 mM potassium 
ferricyanide, 16 mM potassium ferrocyanide, and 2 mM MgC12 in PBS. 
Stains were filtered with 0.45/~m embranes and incubated with tissue sec- 
tions for 14-18 h at 37°C. Sections were rinsed twice for 15 rain sequentially 
with 3% DMSO in PBS followed by PBS alone, reflxed twice with 2% 
paraformaldehyde-0.2 % glutaraldehyde for 15 min, dehydrated inethanol 
(70, 80, 95, and 100%) cleared in xylene, and mounted with Permount 
(Fisher Scientific, Pittsburgh, PA). 
Embryos were recovered on day 14.5 of gestation (0.5 corresponds tothe 
day the vaginal plug was observed) and fixed overnight at 4°C in 2% 
paraformaldehyde-0.2% glutaraldehyde in PBS. Embryos were stained 
with X-gal, processed (to post fixation step) as described above, and pho- 
tographed. 
SubceUular F actionation 
Organs were rapidly dissected from mice and frozen on dry ice. Transgenic 
animals were identified by incubating a small section of cervical spinal cord 
in X-gal stain described above. Tissues were homogenized in0.32 M su- 
close (10% wt/vol), and membrane fractions were obtained by a modifica- 
tion of the methods of Whittaker and Barker (1972) and Norton and Poduslo 
(1973). Briefly, homogenates were centrifuged for 11 rain at 1,000 g to 
generate PI and SI. SI was centrifuged at 17,000 g for 60 min to generate 
$2 and 1>2. $2 was centrifuged for 60 min at 100,000 g to generate the 
microsomal fraction and a soluble fraction. P2 was resuspended in 0.32 M 
sucrose and layered ever a discontinuous sucrose gradient containing 12 mi 
1.2 M sucrose and 12 mi 0.88 M sucrose, and centrifuged for 2 h at 53,000 g 
to generate P2A and P2B at the two interfaces and a pellet, P2C, which 
was resnspended asa mitochondrial fraction. P2A and P2B were diluted 
with water and recentrifuged at 75,000 gfor 30 min. The resulting P2B pel- 
let was the synaptosomal fraction, and P2A was the myelin fraction. Typi- 
cally prepared crude nuclear preparations (P1 fraction) contained sig- 
nificant myelin contamination (data not shown). Nuclei for these studies 
were therefore prepared by centrifugation of the original 0.32 M sucrose 
brain homogenate through sucrose gradients containing 0.88, 1.2, and 1.8 M 
sucrose for 5 h. The resulting pellet was the nuclear fraction. 
Samples were assayed for ~-galactosidase activity by the method of Lira 
and Chae (1989). Samples were incubated with 3.5 mM o-nitrophenyl-/~-D- 
galactopyranoside (ONPG; Sigma Immunochemicals, St.Louis, MO), in 
PBS containing 0.5 % NP-40 for 30 rain at 37°C. Enzyme activity was mea- 
sured as absorbance at420 am. 
Northern Blot Analysis 
Total RNA was isolated according to the procedure of Chomczynski and 
Sacchi (1987) of which 20 /~g was fractionated on 0.68 M formalde- 
hyde-l.0% agarose gels and transferred tonitrocellulose filters in 20x SSC. 
Random primed probes were used to detect sequentially: LacZ (Sphl-NotI 
fragment from pGALAK described above), PLP (EcoRI fragment from 
pKK1.38; Macklin et al., 1991), and pCHOB (BamHI fragment from 
pCHOB; Harpold et al., 1979) transcripts. 
Cell Culture and Immunohistochemistry 
Primary mixed glial cultures (line 26H) were established according to Ed- 
mond et al. (1987). Briefly, cerebral hemispheres were dissected from neo- 
natal mice (3 d old), freed of meninges, and mechanically dissociated in 
Ham's F-12/DME 1:1 (Irvine Scientific, Santa Ana, CA) containing 6 g/liter 
glucose and 10% FBS. The dissociated cells were plated onto 12-mm poly- 
L-lysine-coated glass coverslips in 24-well plates or directly in poly-L-lysine 
coated 6-well plates. Growth medium was changed every 3 d. After the indi- 
cated days in culture, ceils were rinsed twice in PBS without Ca 2+ and 
Mg 2+, and fixed for 1 h at room temperature with 4% paraformaldehyde 
in PBS, pH 7.3. Cells were washed twice with PBS and stored at 4°C in 
PBS until use. The cells were permcabilized with 0.1% Triton X-100 in TBS 
(50 mM Tris, 150 mM NaC1, pH 7.4) for 10 rain, rinsed with PBS and in- 
cubated in 5% normal goat serum in TBS for 1-2 h at room temperature. 
Galactosylceramide mAb (GC; Ranseht et al., 1982) was a kind gift from 
Joyce Benjamins (Wayne State University, Detroit, MI) and polyclonal 
~-galactosidase antibody was purchased from Organon Teknika-Cappel 
(Durham, NC). Appropriate antibody dilutions were made in 5% goat se- 
rum in TBS, added to the fixed, permeabilized cells and incubated for 1 h 
at room temperature. After 4 rinses with PBS, cells were incubated for 1 h 
at room temperature with fluorescein-isothiocyanate- or rhodamine-conju- 
gated, species-specific secondary antibodies (Boehringer-Mannheim Bio- 
chemicals, Indianapolis, IN). After staining, coverslips were mounted with 
vinol mounting medium. 
Results 
PLP-LacZ Transgenic Mice 
We developed a transgenic mouse model to study the spatial 
and temporal regulation of PLP gene expression in particu- 
lar, and to serve as a useful marker of oligodendrocytes in
general. The transgene was generated from two overlapping 
genomic lambda clones, KK1 and 9a (Fig. 1 A). An ApaI site 
in exon 2 was converted to a SphI site with synthetic linkers, 
thereby transforming the 5' ApaI site to a unique site. The 
transgene contained 2.4 kb of 5'-flanking PLP DNA, all of 
exon 1 and intron 1, and the first 37 bp of exon 2 fused in 
frame to the LacZ gene. Therefore, the 5'- and 3'-splice sites 
of intron 1 were maintained for correct splicing, and the fu- 
sion protein contained the initiating methionine and the first 
13 amino acids of PLP in addition to/3-galactosidase se-
quences. The transgene (ApaI-NotI fragment) was purified 
away from vector sequences and microinjected into fertilized 
mouse eggs; 41 pups were born, and 34 survived to be 
screened. These mice were screened for the presence of 
LacZ sequences by Southern blot analysis of genomic DNA 
obtained from tail biopsies. Three founder mice bearing 
multiple copies of the PLP-LacZ construct were identified, 
and lines 20, 26, and 27 were established from these animals 
(Fig. 1 B). One of the lines, line 26, was characterized in 
greatest detail. Founder 26 was chimeric in her germline, 
and her transgenic progeny contained either a high copy 
number (Fig. 1 B, lane 26H) or low copy number (lane 26L) 
of the transgene (Fig. 1 B). The diversity in line 26 probably 
arose from a partial internal detection of multiple head to tail 
insertions of the transgene at a single chromosomal locus in 
the founder (data not shown). The two sublines have been 
maintained stably for over a year without any detectable 
change in transgene copy number suggesting that the inser- 
tion site was not at a recombinational "hot" spot. All three 
lines expressed the transgene based upon X-gal staining. The 
expression of the transgene in either subline of 26 or in line 
27 was generally at a consistently high level, as determined 
by histological assay. Thus, lines 26H, 26L, and 27 were 
characterized further. Since line 20 expressed the transgene 
to a lower extent, it was not characterized in detail, although 
line 20 did express the transgene in a tissue-specific manner 
(see below). 
PLP-LacZ Transgene Expression Is Tissue Specific 
The tissue specificity of transgene expression was studied by 
Wight et al. Proteolipid Protein-LacZ Transgene Expression and Targeting 445 
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Figure L Generation of trans- 
genic mice. (A) Structure of 
the mouse PLP gene and 
the PLP-LacZ transgene. The 
relevant structure of the 
mouse PLP gene including 
2.4 kb of the 5' upstream re- 
gion and the entire exon- 
intron area is illustrated at the 
top. The gene structure is 
presented in a 5' to 3' orienta- 
tion, with exons represented 
by black boxes. Overlapping 
lambda genomic clones, KK1 
and 9a, were used to recon- 
strnct PLP intron 1 and gener- 
ate the transgene shown at the 
bottom of the figure. The 
transgene encompassed PLP sequences starting with a 5' end 2.4 kb upstream from the cap site and proceeding downstream tothe ApaI 
site in exon 2. The ApaI site in exon 2 was mutated to a SphI site, thus making the 5'Apal site unique in the transgene. The PLP sequences 
were fused in frame to a LacZ expression cassette (see Materials and Methods ection for details). The ApaI-NotI fragment was purified 
away from vector sequences (indicated by wavy lines) and microinjected into fertilized mouse ggs to produce transgenic mice. Restriction 
sites are indicated as follows: ApaI, A; BamI-II, B; mutated ApaI site, A"'Sph; NotI, N. (B) Southern blot analysis of genomic DNA isolated 
from PLP-LacZ transgenic lines. Genomic DNA (10 #g) was digested with BamI-II, fractionated on 0.7% agarose gels, transferred to 
nitrocellulose, hybridized to 32p randomly primed fragments prepared from the LacZ region (SphI-Notl) shown in (A). The autoradio- 
gram shown on the left compares results obtained from lines 20, 27, and 26H while the autoradiogram onthe right contrasts he two sublines 
originating from founder animal 26. 
analyzing LacZ mRNA levels and B-galactosidase enzyme 
activity. Total RNA was isolated from the liver, lung, heart, 
kidney, spleen, spinal cord, and brain of a 21-d-old mouse 
from line 26H. PLP-LacZ and PLP transcripts were de- 
tected only in the spinal cord and brain (Fig. 2). Similar 
results were obtained for enzyme activity, using tissue 
homogenates made from transgenic (26L and 27) and non- 
transgenic mice. B-galactosidase activity was present at de- 
tectable levels only in the brains and spinal cords of trans- 
genie mice (Fig. 3). Enzyme activity was below the limits 
of detection in sciatic nerve, heart, liver, lung, spleen, kid- 
ney, or testes. However, when intact sciatic nerve from all 
three transgenic lines was incubated in X-gal buffer, B-galac- 
tosidase activity could be detected (data not shown). The 
length of time required for development of the blue reaction 
product was consistent with the known levels of transgene 
expression in these animals, i.e., sciatic nerve from lines 26 
and 27 generated blue reaction product within a few hours, 
while sciatic nerve from line 20 required overnight incuba- 
tion and nontransgenic s iatic nerve remained white. When 
sciatic nerve homogenates were analyzed by Western blot, 
sciatic nerve samples from lines 26 and 27 had detectable 
Figure 2. Northern blot analy- 1.4- 
sis of mRNA expression i  tis- 
sues. Total RNA was isolated 1.2- 
from the indicated tissues of a 
21-d-old transgenic mouse • 1.o- 
(line 26H). 20 #g was frac- ~ .a- 
tionated by electrophoresis ca 
through a denaturing formal- o .6- 
dehyde agarose g l (1%) and 
transferred to a nitrocellulose .4- 
filter. The blot was probed se- .2- 
quentially for LacZ, PLP, 
and CHOB transcripts. RNA 0 
loading was consistent among 
lanes, as judged by CHOB 
mRNA, which is encoded by 
a constitutively expressed 
gene (data not shown). Shown 
are the resulting autoradio- 
grams for (A) PLP mRNA; 
19-h exposure and (B) PLP-LacZ mRNA; 9<1 exposure. The 
PLP-LacZ mRNA is slightly longer than the 3.2-kb mRNA for 
PLP. S.C., spinal cord. 
[ ]  26 
[ ]  27 
F 7 -~ r--~ ~ 7 -~ r--~ r--~ . . . .  
brain spinal sciatic heart liver lung spleen kidney testes 
cord nerve 
I 
Figure 3. Spatial pattern of B-galactosidase activity. Tissues were 
isolated from adult transgenic mice (Line 26L and 27). Homoge- 
nates were prepared in PBS, and samples were incubated with 3.5 
mM ONPG, 0.5% NP-40 in PBS (Lira and Chae, 1989). Samples 
were 20/xg of brain and spinal cord protein from line 26H, 5 t~g 
of brain and spinal cord protein from line 27 and 100 #g protein 
from other tissues. Samples were incubated for 2 h and optical den- 
sity was measured at 420 nm. 
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/~-galactosidase bands, which were present at significantly 
lower levels than those from brain or spinal cord; heart sam- 
pies had no detectable /~-gaiactosidase band (data not 
shown). No immunoreactive B-galactosidase band was seen 
in sciatic nerve from line 20, but this was not unexpected 
since the amount of immunoreactive B-galactosidase in the 
brain and spinal cord of line 20 mice was extremely ow. The 
inability to detect/3-gaiactosidase activity in sciatic nerve 
from any transgenic line in our enzyme assay or on Western 
blots of sciatic nerve from line 20 presumably reflects the ex- 
tremely low level of the protein that is expressed in this tis- 
sue. The selective xpression of the transgene i  brain, spi- 
nal cord, and at low levels in sciatic nerve indicates that the 
transgene contained the PLP genomic sequences necessary 
to direct tissue specific expression. 
Expression of the PLP-LacZ Transgene Is
Developmentally Regulated 
Examination of 20-30-#m brain sections tained with X-gal 
revealed that transgene expression (as measured by/3-galac- 
tosidase activity) increased with age and that staining ap- 
peared to localize to white matter areas within the brain (Fig. 
4). Similar developmental patterns were seen for line 27 and 
both sublines of line 26. While abundant blue staining was 
apparent inthe transgenic animals, no staining was observed 
in the brains and spinal cords of nontransgenic l ttermates 
(data not shown)./~-galactosidase activity was evident in the 
brains of mice (line 26H) at postnatal day 5 and increased 
significantly up to day 21 generally following acaudal to ros- 
tral gradient (Fig. 4). By day 5, transgene expression was de- 
tected in the regions of the olfactory tract, hindbrain, and 
faintly in the midbrain. Stain was first observed in the white 
matter tracts of the cerebellum at day 7 and rapidly in- 
creased, reaching saturating levels by day 21. Enzyme activ- 
ity was detected in the diencephalon by day 8 and in the 
corpus callosum by day 12. Thus, transgene expression was 
regulated temporally and followed a caudal to rostral pat- 
tern, consistent with normal myelination. B-galactosidase 
activity in line 26L, which contained substantially ower 
copies of the transgene, showed temporal regulation as well, 
albeit to a slightly lower level than line 26H in younger 
animals (data not shown). 
Northern blot analysis was performed to evaluate the tem- 
poral expression of transgenic PLP-LacZ and endogenous 
PLP mRNAs in the brains of mice from line 26L. Total RNA 
isolated from the brains of mice ages 2-28 d exhibited a de- 
velopmental increase in PLP-LacZ mRNA (Fig. 5 B). The 
largest change in PLP-LacZ mRNA levels occurred between 
9 and 12 d. Correspondingly, the three major size classes of 
mRNAs generated from the mouse PLP gene (3.2, 2.4, and 
1.6 kb) are regulated evelopmentally and showed the 
greatest increase between 9 and 12 d (Fig. 5 A; the autora- 
diogram was overexposed in order to detect the 3.2-kb tran- 
script in 2-d-old brain). The levels of PLP-LacZ mRNA 
were comparatively less than the PLP mRNAs at all times 
examined, except perhaps in the 2-d brain sample. Interest- 
ingly, the slope of the increase in PLP-LacZ mRNA levels 
was not as great as that for endogenous PLP transcripts. 
The Transgene IsExpressed in
Cultured Oligodendrocytes 
To assess the cell type responsible for transgene expression, 
blue-stained regions from the brain were examined under 
high magnification (100×). Cells demonstrating B-gaiac- 
Figure 5. Northern blot analy- 
sis of developmental mRNA 
expression in brain. Total 
RNA was isolated from brains 
of transgenic mice (line 26L) 
at the indicated ages (postna- 
tal days 2 through 28) and 
processed as described in Fig. 
2. The blot was probed se- 
quentially for LacZ, PLP, 
and CHOB transcripts. RNA 
loading was consistent among 
lanes as determined by hy- 
bridization with the CHOB 
probe (data not shown). 
Shown are the resulting au- 
toradiograms for (A) PLP 
mRNA; 19-h exposure and 
(B) PLP-LacZ mRNA; 4-d 
exposure. 
Figure 6. Morphology of transgene expressing cells. High 
magnification (100 x objective) of Bluo-gal-stained cells from 
brains of transgenic mice at the indicated ages. Staining showed 
cells with bipolar and stellate morphologies at the younger ages 
with a progression t  highly arborized cells and white matter tracts 
staining by postnatal day 12. 
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Table L Immunocytochemical Quan@cation of 
~-galactosidase (f3-Gal) and GC Expressing Cells in 
Primary Brain Cultures 
Days in culture B-Gal-positive cells GC-positive cells /~-Gal/GC 
% 
9 8 11 72 
14 28 34 82 
22 66 73 90 
28 30 33 90 
Mixed primary glial cultures were prepared from neonatal transgenic brains 
(line 26H). Cells were fixed and double stained forB-galactosidase (a-Gal) and 
GC immunoreactivity. Three fields (200x) were examined at each time point 
and quantified for B-Gal and GC immunoreactivity. Shown are the total num- 
ber of immunoreacdve cells from the three fields as well as the percentage of
GC-positive cells that were also p sitive for/3-Gal. B-Gal positive cells were 
always positive for GC immunoreactivity. 
tosidase activity were morphologically consistent with oli- 
godendroglial development. Bipolar and steUate cells were 
observed at the younger ages with a progression tohighly ar- 
borized cells and white matter tracts staining at the older 
ages (Fig. 6). To identify these cells positively as oligoden- 
drocytes, primary mixed glial cultures were prepared from 
neonatal transgenic mouse brains and immunocytochemi- 
cally evaluated for the oligodendroglial-specific marker, 
galactosylceramide (GC). When quantified for the number 
of GC and/~-galactosidase immunoreactive cells, it was clear 
that at all ages studied,/3-galactosidase was present only in 
cells that were also GC positive (Table I). Thus, the trans- 
gene was not expressed in astrocytes or microglia in these 
cultures. In addition, as cultures matured, an increasing per- 
centage of GC-positive cells became/3-galactosidase po itive, 
until by 22-28 d in culture, 90% of the GC-positive cells 
were/3-galactosidase positive. 
The Transgene Is Expressed in Embryos 
To evaluate PLP-LacZ expression during embryonic devel- 
opment, a male heterozygous for the transgene (line 26H) 
was bred to a nontransgenic female, and 14.5-d embryos 
were analyzed for/~-galactosidase ctivity. X-gal staining 
was observed throughout the dorsal root ganglia nd in the 
olfactory bulb in transgenic embryos at embryonic day 14.5 
(Fig. 7). Significant staining of most PNS tracts was ob- 
served also. In fact, more PNS staining was observed than 
CNS staining. No staining was evident in nontransgenic lit-
termates. 
The Fusion Protein Is Targeted to the Myelin 
The subcellular localization of the transgene product was 
studied by EM and subcellular fractionation. Electron 
micrographs of Bluo-gal-stained tissue suggested that the 
enzyme activity was localized in the compact myelin (Mack- 
lin et al., 1993). To confirm this, brain homogenates were 
fractionated and assayed for ~-galactosidase activity. Dra- 
matically higher levels of enzyme activity were detected in 
the myelin fraction prepared from transgenic brains than 
other tissues (Fig. 8). Thus, the nuclear, synaptosomal, mi- 
tochondrial, microsomal, and supernatant fractions from 
transgenic brains showed very little/3-galactosidase ctivity. 
The small amount of activity in the synaptosomal fraction 
Figure 7. Transgene expression in 14.5-d embryos. Whole fetuses 
were stained for/3-galactosidase activity with X-gal. Staining is 
evident in the dorsal root ganglia and the olfactory bu b of rans- 
genie embryos but not in nontransgenic littermates. 
was probably from myelin contamination, since this fraction 
contained PLP, as determined by Western blots (data not 
shown). Essentially no activity was found in fractions ob- 
tained from nontransgenic brains. The enrichment ofactiv- 
ity in myelin was found for all three transgenic lines, al- 
though the level of activity in myelin from line 20 was quite 
low. These data demonstrate that the first 13 amino acids of 
PLP were sufficient to target the fusion protein to the myelin, 
and generally to no other subcellular fraction, including 
cytosol. 
1.8- 
1.6- 
1.4- 
E 1.2- 
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Cell Fraction 
Figure 8. /3-galactosidase ctivity in subcellular brain fractions. 
fl-galactosidase activity was measured by incubating samples in 3.5 
mM ONPG for 30 rain and measuring absorbance at 420 nm. Sam- 
ples, lines 26H and 27, 25 #g; line 20, 200 #g. 
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Discussion 
The mechanisms that control oligodendrocyte differentiation 
in the developing nervous ystem have a major impact on 
many aspects of brain development. Oligodendrocytes are 
among the most abundant cells in the nervous ystem, and 
if their differentiation program is disrupted, many areas of 
the CNS are'peramnently impaired. These cells have a very 
well defined differentiation program, which can be inves- 
tigated extensively insitu and in culture. Because they repre- 
sent a relatively homogeneous cell population, which ex- 
presses a small set of myelin-specific genes, and because 
their differentiation program can proceed in culture in the 
absence of other cells and trophic factors, these cells are 
ideally suited for studies designed to understand lineage and 
the control of differentiation in the CNS. In fact, they have 
become an important model for investigating many of these 
quesU.'ons. The current studies focus on one of these 
oligodendrocyte-specific genes; they investigate what re- 
gions of the PLP gene are important for tissue-specific ex- 
pression, and how its expression is controlled in the develop- 
ing nervous ystem. 
The presence of positive or negative tissue-specific regula- 
tory elements within introns has been demonstrated fora va- 
riety of genes including immunoglobulin heavy chain 
(Banerji et al., 1983; Gillies et al., 1983) and light chain 
genes (Queen and Baltimore, 1983; Picard and Schaffner, 
1984; Pierce et al., 1991), collagen genes (Bornstein et al., 
1987; Horton et al., 1987; Burbelo et al., 1991), and genes 
encoding adenosine deaminase (Aronow et al., 1989), 
~-globin (Magram et al., 1989), Thy-1 (Vidal et al., 1990), 
apolipoprotein B (Brooks et al., 1991), glial fibriUary acidic 
protein (Sarker and Cowan, 1991), p53 (Lozano and Levin, 
1991), and PDGF-B (Franklin et al., 1991). We hypothesized 
that the mouse PLP gene might contain tissue-specific 
regulatory element(s) within the first intron since (a) the 
transfection results analyzing PLP promoter elements did 
not define unambiguously a tissue-specific element within 
the 5'-flanking DNA (Ikenaka et al., 1990; Nave and Lemke, 
1991; Berndt et al., 1992; Cook et al., 1992); (b) the topol- 
ogy of the PLP gene is highly conserved evolutionarily; and 
(c) almost half of the PLP gene is contained within the first 
intron. A transgenic approach was used to test this hypothe- 
sis. In these studies, the transgene consisted of PLP se- 
quences encompassing 2.4 kb of 5'-flanking DNA, all of 
exon 1 and intron 1, and the first 37 bp of exon 2 fused in 
frame to a LacZ expression cassette (Fig. 1 A). It should be 
noted that he presence of introns has been shown to increase 
the expression of transgenes in mice (Brinster et ai., 1988; 
Choi et al., 1991; Palmiter et al., 1991). Thus, the inclusion 
of the first intron in our transgene may have been important 
from a nonspecific and/or technical perspective for trans- 
gene expression, and not because of specific enhancers 
within the intron. While our PLP-LacZ fusion gene did not 
specifically map tissue-specific regulatory element(s) of the 
PLP gene, the transgene appears to contain such elements, 
and we are generating additional transgenic lines with dele- 
tions in the first intron to test our hypothesis that such ele- 
ments reside there. 
The fusion gene contained sequence(s) ufficient to permit 
spatial and temporal regulation of the transgene ina manner 
similar to endogenous CNS PLP gene expression. PLP- 
LacZ and endogenous PLP/DM-20 transcripts were detected 
in the spinal cord and brain of a 21-d-old mouse (line 26H), 
and not in liver, lung, heart, kidney, nor spleen (Fig. 2). Par- 
allel results were obtained when tissue homogenates were as- 
sayed for/3-gaiactosidase activity (Fig. 3). One potential 
difference exists between expression of the transgene and the 
normal PLP gene. Recently, DM-20 mRNA has been found 
in the heart (Campagnoni etai., 1992). We were unable to 
detect any /3-galactosidase activity in heart homogenates 
prepared from adult transgenic mice (Fig. 3). Perhaps the 
enzymatic activity was diluted to undetectable levels by non- 
expressing constituents in these tissues, or possibly expres- 
sion is reduced evelopmentally in the adult. Campagnoni 
et al. (1992) estimated that the level of PLP/DM-20 mRNA 
in the heart was ,,o0.1-0.2% of that in the brain. Conceivably 
our Northern blot analysis was below detection limits, since 
total RNA instead of poly(A) ÷ RNA was used in our 
studies. However, since we were also unable to detect enzy- 
matic activity or/3-galactosidase protein in Western blots 
of heart samples, it is possible that the PLP genomic se- 
quences necessary for mature myocardial expression are ab- 
sent from the fusion gene and reside elsewhere in the PLP 
gene. 
The PLP gene is expressed ata low level in Schwann ceils 
(Puckett et ai., 1987; Griffiths et al., 1989; Stahl et al., 
1990; Agrawal and Agrawal, 1991; Gupta et al., 1991; 
Pham-Dinh et ai., 1991; Ikeneka et al., 1992; Kamholz et 
al., 1992; Timsit et al., 1992a). 5-galactosidase was present 
in sciatic nerves prepared from adult mice in all three trans- 
genic lines. The enzyme activity was below the levels of de- 
tection with our enzyme assay, but other techniques demon- 
strated its presence. It is possible that the protein was 
undetectable in the enzyme assay because of its extremely 
low level. The Western blots suggest that he level of the pro- 
tein in sciatic nerve is 2-5 % that in brain. On the other hand, 
it is also possible that he inability to detect it in the enzyme 
assays results from lower enzyme stability in sciatic nerve 
than in brain. This possibility is suggested by the fact that 
intact sciatic nerve stained well with X-gal, and the length 
of time needed for the staining was not dramatically onger 
than that needed for intact spinal cord from the same trans- 
genic line. While X-gal staining is not an accurate quantita- 
tive measure of enzyme activity, it is dependent upon the 
amount of enzyme present, and both spinal cords and sciatic 
nerves from lines 26 and 27 reacted histochemically much 
more rapidly than did spinal cords and sciatic nerves from 
line 20. Thus, it was somewhat surprising that no enzyme ac- 
tivity could be detected in sciatic nerve homogenates in the 
ONPG enzyme assay, since spinal cord and brain homoge- 
nates had measureable enzyme activities in this assay. Per- 
haps the/~-galactosidase enzyme in sciatic nerve is more la- 
bile than the CNS/~-galactosidase, which could be protected 
from denaturation bylocalization to the myelin membrane. 
It is unclear at present where the/~-galactosidase protein is 
localized in sciatic nerve, but it has been reported that the 
PLP/DM-20 protein in Schwann cells is not present in PNS 
myelin, but is in the cell body (Puckett et al., 1987). Thus, 
the #-galactosidase activity could be more stable in myelin 
than in the soma. 
Transgene xpression was quite extensive in embryonic 
PNS, as well as in discrete regions of the embryonic brain, 
which received irect PNS input. As shown in Fig. 7, the 
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dorsal root ganglia and olfactory bulb stained intensively 
with X-gal in embryos at gestational day 14.5. As well, blue 
tracts were evident in the limbs, even extending out into the 
digits of some embryos. This may be correlated to endoge- 
nous DM-20 expression since DM-20 mRNA expression 
precedes that of PLP and appears to predominate in the em- 
bryo (Pham-Dinh et al., 1991; Ikenaka et al., 1992; Timsit 
et al., 1992a). What cell type in either the embryonic CNS 
or PNS is expressing the transgene and what the function of 
a PLP gene product is in these embryos are intriguing and 
important questions. Does DM-20 act in embryonic cells of 
the glial lineage to control some aspect of their differentia- 
tion? How does this protein, which appears to function in 
myelin as a hydrophobic structural protein in a multilarnellar 
membrane, function in embryos, which have no such mul- 
tilamellar membranes? These questions are being inves- 
tigated with our transgenic lines. 
The PLP-LacZ fusion gene also contained the necessary 
PLP genomic sequences todirect emporal expression of the 
transgene. Developmental regulation of transgene xpres- 
sion exists for LacZ mRNA as shown by Northern analysis 
(Fig. 5). A substantial increase occurred between 9 and 12 d 
for both PLP-LacZ and endogenous PLP transcripts. The 
levels oftransgene mRNA were less than those for PLP/DM- 
20 mRNAs at all ages studied. Similar esults were obtained 
with a MBP-LacZ transgene (Gow et al., 1992). Interest- 
ingly, the slope of the increase of PLP-LacZ transgene 
mRNA levels during development was quite different from 
that of the endogenous PLP mRNA. The PLP-LacZ mRNA 
increase appeared to be relatively consistent throughout de- 
velopment, while the PLP mRNA increase was more dra- 
matic between 9 and 12 d. In other studies, we have demon- 
strated that the transcription rate of the PLP gene increases 
during development by several fold (Macklin et al., 1991). 
Since PLP mRNA levels rise by orders of magnitude during 
development, the transcription rate cannot be solely respon- 
sible for the increase in mRNA levels, which suggests that 
another level of PLP gene regulation must exist postranscrip- 
tionally. Other studies investigating the mechanisms control- 
ling PLP gene expression have suggested that protein kinase 
C activity may control some aspect of PLP mRNA stability 
in differentiating oligodendrocytes (Asotra and Macklin, 
1993). This mRNA stability could be controlled by second- 
ary structure within the >2,000 bases of the 3'-noncoding 
segment of the PLP/DM-20 mRNAs. Since this segment is
not present in the PLP-LacZ fusion transcript, transgene 
mRNAS would not be controlled in the same manner. On the 
other hand, that region of the PLP mRNA was included in 
the transgene expressed by Gow et al. (1992), and it did not 
appear to stabilize LacZ transcripts to any great extent. 
The transgene was expressed in primary mixed glial cul- 
tures derived from neonatal brains. Immunocytochemical 
analysis howed the/3-galactosidase ctivity was found only 
in putative oligodendrocytes, i.e., all /3-galactosidase im- 
munoreactive c lls were immunoreactive also for GC, a 
marker for immature as well as mature oligodendrocytes (Ta- 
ble I). These data imply that oligodendrocyte progenitors do 
not express the transgene, since GC appears only in imma- 
ture and mature oligodendrocytes, not in progenitors, which 
express A2B5 prior to GC (Raft et al., 1983). However, low 
levels of transgene expression probably would be below the 
levels of detection by immunocytochemistry. As cells ma- 
tured in the mixed culture, and presumably begin to express 
more PLP, the number of B-galactosidase positive cells in- 
creased, as did the percentage ofGC positive cells that were 
/3-galactosidase positive. The subpopulation f oligodendro- 
cytes that did not express the PLP-LacZ fusion gene at de- 
tectable l vels was reduced with time in culture, and in older 
cells only 10% of GC positive cells did not appear to express 
B-galactosidase. 
Since the immunoreactivity for B-galactosidase colocal- 
ized with that for PLP, subcellular localization of the fusion 
protein was investigated. Intriguingly, the transgene product 
was localized in the myelin membrane itself as determined 
by EM and subcellular f actionation of brain homogenates 
(Fig. 8). Thus it appears that he first 13 amino acids of PLP 
are sufficient to target the protein to myelin. Whether target- 
ing to the myelin sheath is the result of an active process or 
a passive vent, such as association ofthe short PLP peptide 
with the endogenous PLP/DM-20 proteins remains to be de- 
termined. It is noteworthy that, although PLP/DM-20 tran- 
scripts are translated on bound ribosomes (Colman et al., 
1982), the microsomal fraction did not contain any B-galac- 
tosidase activity, suggesting that this chimeric protein is 
localized primarily in the sheath and is not retained in the 
endoplasmic reticulum. This is intriguing in that when DM- 
20 cDNA is transfected into HeLa cells, the protein accumu- 
lates predominantly in vesicles, presumably ER and Golgi, 
although some DM-20 protein moves to the plasma mem- 
brane (Timsit et al., 1992b). Thus, a more complete move- 
ment o the myelin membrane is effected with our PLP-LacZ 
fusion protein in situ, which does not accumulate in vesicles. 
This suggests that some cell-specific or developmental f c- 
tors are important for the movement ofthese proteins within 
oligodendrocytes. 
These data on the localization of the PLP-LacZ fusion 
protein are extremely important since they imply that a very 
small segment of this protein is sufficient o target it ap- 
propriately. Related data have been presented for cyto- 
chrome b5, where the carboxy-terminal 10amino acids ap- 
pear sufficient to target he protein to the ER (Mitoma and 
Ito, 1992), and for growth-associated protein (GAP-43) 
where the NH2-terminal 10 amino acids have been reported 
to target reporter proteins to the growth cone in transfected 
cells (Zuber et al., 1989), although other eports about rans- 
fection of GAP-43 reporter constructs do not agree with the 
initial observation (Liu et al., 1991). Similarly, the first 12 
amino acids (less than half of the presequence) of an im- 
ported mitochondrial protein could direct mouse cytosolic 
dihydrofolate r ductase into the yeast mitochondrial matrix 
(Hurt et al., 1985). It should be noted that not all transgenic 
products in oligodendrocytes will target o the myelin mem- 
brane. For example, Gow et al. (1992) did not find B-galac- 
tosidase in the myelin membrane in their MBP-LacZ mice. 
A search of the current data bases for sequence homology 
to the NH2-terminal 13 amino acids of PLP did not reveal 
any significant identity to other proteins. However, iden- 
tification of targeting sequences solely by sequence analysis 
is often times insufficient. For instance, many random se- 
quences can functionally replace the secretion signal se- 
quence of yeast invertase for targeting to the plasma mem- 
brane (Kaiser et al., 1987). Nonetheless, everal of the 
amino acids in the NH2-terminal portion of PLP warrant 
further discussion. Myristoylation of NH2-terminal glycine 
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residues such as in Rous sarcoma virus ppt0src has been 
shown to be important in targeting proteins (Pellman et al., 
1985). Although PLP is acylated and it contains an NH2- 
terminal glycine, the NH2 terminus is not blocked and the 
predominant fatty acid is palmitic acid (Lees and Bizzozero, 
1992). Recently, it has been shown that PLP cysteine 
residues at positions 5, 6, 9, 108, 138, and 140 are modified 
by long-chain fatty acids (Weimb and Stoffel, 1992). Thus, 
acylation of the first three cysteine residues may be important 
in targeting our fusion protein. On the other hand, PLP acy- 
lation has been shown to occur within the myelin membrane 
itself (Lees and Bizzozero, 1992), suggesting that covalent 
lipid modifications may not be important for targeting this 
protein. A di-leucine motif has been implicated in lysosomal 
targeting of T cell antigen receptor chains (Letourneur and 
Klausner, 1992), but our results did not indicate targeting of 
the fusion protein to the lysosome even though leucine 
residues are found in positions two and three of PLP. 
The observation that the NH2-terminal 13 amino acids of 
PLP were sufficient o target the fusion protein to the myelin 
membrane does not preclude the possibility that multiple 
recognition determinants may exist within the protein. The 
human low density lipoprotein receptor was recently shown 
to contain two different determinants that independently 
mediated sorting to the basolateral plasma membrane in 
MDCK cells (Matter et al., 1992). Additionally, targeting of 
multimeric proteins may require specific interactions of the 
subunits, and some multimeric proteins that fail to assemble 
correctly are not transported to their proper location. The 
NH2-terminai domains of acetylcholine receptor subunits 
have been shown to contain recognition signals for the initial 
steps of receptor assembly (Verrall and Hall, 1992). It has 
been postulated that the PLP aggregates to form channels 
within the myelin membrane (Lees and Bizzozero, 1992). 
Thus, targeting of our fusion protein to the myelin mem- 
brane could be explained if the NH2-terminal region of PLP 
was important in PLP aggregation. 
The presence of/3-galactosidase, which is a relatively 
large protein (,o120 kD), in the myelin membrane has had 
no discernible ffect on the function or stability of the myelin 
in these animals. Heterozygous adult mice (6-9 mo) from 
several ines and homozygous adult mice from line 26 have 
no obvious clinical signs of dysmyelination, and electron 
micrographs of adult tissue indicate no dramatic alteration 
in the appearance of compact myelin. Nevertheless, the pres- 
ence of the enzyme in the myelin membrane alters it at some 
level, since staining of the membrane for enzyme activity 
disrupts compact myelin extensively (data not shown). 
Studies are under way to localize the enzyme more discretely 
within the myelin sheath. 
The current studies have demonstrated that PLP-LacZ 
transgene xpression is an excellent measure ofPLP gene ex- 
pression in embryos and postnatal animals, as well as in pri- 
mary cultured oligodendrocytes. These cells are now tagged 
with LacZ with no apparent detrimental effect, and they 
should be ideal for transplantation studies. Further investiga- 
tions into the consequences of targeting a new protein into 
the myelin membrane itself may provide important new in- 
sights into myelination and dysmyelination. 
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